Iqvia (IQV) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $266.90, -1.53% vs the prior close of $271.04.
- Volume 1.04M shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IQV dips 1.5% to $266.90. Closed at $266.90, -1.53% vs the prior close of $271.04. Day range $263.21–$272.98, opened at $271.92.
IQV daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — IQV dips 1.5% to $266.90
- Closed at $266.90, -1.53% vs the prior close of $271.04. Day range $263.21–$272.98, opened at $271.92.
- Volume was 1.04M shares, 0.7x its 50-day average of 1.39M.
- Price is +2.6% vs its 50-day average ($260.02) and +28.5% vs its 200-day average ($207.74).
- 52-week range $154.50–$277.40; today's close sits at 91% of that range, 3.8% below the 52-week high.
Oct 15, 2026 — IQV jumps 3.4% to $271.04
- Closed at $271.04, +3.45% vs the prior close of $262.01. Day range $261.77–$271.68, opened at $265.10.
- Volume was 1.46M shares, 1.0x its 50-day average of 1.39M.
- Price is +4.5% vs its 50-day average ($259.33) and +30.6% vs its 200-day average ($207.55).
- 52-week range $154.50–$277.40; today's close sits at 95% of that range, 2.3% below the 52-week high.
Oct 14, 2026 — IQV rises 0.5% to $262.01
- Closed at $262.01, +0.51% vs the prior close of $260.68. Day range $260.82–$266.66, opened at $264.37.
- Volume was 1.12M shares, 0.8x its 50-day average of 1.40M.
- Price is +1.3% vs its 50-day average ($258.63) and +26.4% vs its 200-day average ($207.33).
- 52-week range $154.50–$277.40; today's close sits at 87% of that range, 5.5% below the 52-week high.
Oct 13, 2026 — IQV dips 0.6% to $260.68
- Closed at $260.68, -0.58% vs the prior close of $262.21. Day range $259.61–$265.00, opened at $263.49.
- Volume was 1.36M shares, 1.0x its 50-day average of 1.40M.
- Price is +1.1% vs its 50-day average ($257.95) and +25.8% vs its 200-day average ($207.15).
- 52-week range $154.50–$277.40; today's close sits at 86% of that range, 6.0% below the 52-week high.
Oct 12, 2026 — IQV rises 0.9% to $262.21, 3 up days in a row
- Closed at $262.21, +0.90% vs the prior close of $259.88. Day range $257.30–$263.82, opened at $260.23.
- Volume was 1.09M shares, 0.8x its 50-day average of 1.41M.
- Price is +1.9% vs its 50-day average ($257.41) and +26.7% vs its 200-day average ($206.98).
- 52-week range $154.50–$277.40; today's close sits at 88% of that range, 5.5% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — IQV rises 0.4% to $259.88
- Closed at $259.88, +0.39% vs the prior close of $258.88. Day range $257.73–$263.51, opened at $257.73.
- Volume was 972.30K shares, 0.7x its 50-day average of 1.42M.
- Price is +1.2% vs its 50-day average ($256.86) and +25.7% vs its 200-day average ($206.79).
- 52-week range $154.50–$277.40; today's close sits at 86% of that range, 6.3% below the 52-week high.
Oct 8, 2026 — IQV ends flat (+0.3%) to $258.88
- Closed at $258.88, +0.30% vs the prior close of $258.11. Day range $252.56–$259.95, opened at $256.01.
- Volume was 988.40K shares, 0.7x its 50-day average of 1.45M.
- Price is +1.0% vs its 50-day average ($256.42) and +25.3% vs its 200-day average ($206.62).
- 52-week range $154.50–$277.40; today's close sits at 85% of that range, 6.7% below the 52-week high.
Oct 7, 2026 — IQV dips 0.7% to $258.11
- Closed at $258.11, -0.72% vs the prior close of $259.98. Day range $255.05–$261.41, opened at $261.41.
- Volume was 1.41M shares, 0.9x its 50-day average of 1.52M.
- Price is +0.7% vs its 50-day average ($256.19) and +25.0% vs its 200-day average ($206.43).
- 52-week range $154.50–$277.40; today's close sits at 84% of that range, 7.0% below the 52-week high.
Oct 6, 2026 — IQV dips 2.3% to $259.98
- Closed at $259.98, -2.30% vs the prior close of $266.09. Day range $259.79–$274.28, opened at $269.43.
- Volume was 1.11M shares, 0.7x its 50-day average of 1.54M.
- Price is +1.6% vs its 50-day average ($255.89) and +26.1% vs its 200-day average ($206.25).
- 52-week range $154.50–$277.40; today's close sits at 86% of that range, 6.3% below the 52-week high.
Oct 5, 2026 — IQV jumps 3.1% to $266.09
- Closed at $266.09, +3.05% vs the prior close of $258.21. Day range $258.51–$266.91, opened at $258.51.
- Volume was 1.69M shares, 1.1x its 50-day average of 1.53M.
- Price is +4.4% vs its 50-day average ($254.96) and +29.1% vs its 200-day average ($206.05).
- 52-week range $154.50–$277.40; today's close sits at 91% of that range, 4.1% below the 52-week high.
Oct 2, 2026 — IQV dips 1.0% to $258.21, 4 down days in a row
- Closed at $258.21, -0.96% vs the prior close of $260.72. Day range $257.07–$261.98, opened at $260.70.
- Volume was 1.37M shares, 0.9x its 50-day average of 1.53M.
- Price is +1.7% vs its 50-day average ($253.80) and +25.4% vs its 200-day average ($205.83).
- 52-week range $154.50–$277.40; today's close sits at 84% of that range, 6.9% below the 52-week high.
- That makes 4 straight losses.
IQV latest news & SEC filings
Every SEC filing by or about IQV in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Berkshire James G. sold 2,668 shares at $261.33 (≈$697.23K) on Sep 2, 2026
- Berkshire James G. sold 2,668 shares at $261.33 (≈$697.23K) on Sep 2, 2026
- Berkshire James G. sold 2,668 shares at $261.33 (≈$697.23K) on Sep 2, 2026
- Berkshire James G. sold 2,668 shares at $261.33 (≈$697.23K) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Staub W Richard sold 5,500 shares at $232.68 (≈$1.28M) on Aug 3, 2026
- Staub W Richard sold 5,500 shares at $232.68 (≈$1.28M) on Aug 3, 2026
- Staub W Richard sold 5,500 shares at $232.68 (≈$1.28M) on Aug 3, 2026
- Staub W Richard sold 5,500 shares at $232.68 (≈$1.28M) on Aug 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patel Bhavik sold 1,855 shares at $235.27 (≈$436.43K) on Jul 31, 2026
- Patel Bhavik sold 1,855 shares at $235.27 (≈$436.43K) on Jul 31, 2026
- Patel Bhavik sold 1,855 shares at $235.27 (≈$436.43K) on Jul 31, 2026
- Patel Bhavik sold 1,855 shares at $235.27 (≈$436.43K) on Jul 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 3, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 28, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade IQV
- Last results release: Jul 28, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 5, 2026, Oct 28, 2025. Based on that rhythm, the next report is likely around Oct 27, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.26% (largest 3.4%).
- Liquidity: about 1.32M shares (≈$351.98M) trade per day on average.
- 52-week position: $266.90 vs a range of $154.50–$277.40 (91% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: James G. Berkshire sold 2,668 shares on Sep 2, 2026.
- Latest filings: 8-K Sep 23, 2026; 8-K Sep 9, 2026; 10-Q Jul 28, 2026.
- Share count: 166.90M shares outstanding (Apr 30, 2026), -3.5% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Services-Commercial Physical & Biological Research.
IQV market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 271.92 | 272.98 | 263.21 | 266.90 | 1.04M |
| Oct 15, 2026 | 265.10 | 271.68 | 261.77 | 271.04 | 1.46M |
| Oct 14, 2026 | 264.37 | 266.66 | 260.82 | 262.01 | 1.12M |
| Oct 13, 2026 | 263.49 | 265.00 | 259.61 | 260.68 | 1.36M |
| Oct 12, 2026 | 260.23 | 263.82 | 257.30 | 262.21 | 1.09M |
| Oct 9, 2026 | 257.73 | 263.51 | 257.73 | 259.88 | 972.30K |
| Oct 8, 2026 | 256.01 | 259.95 | 252.56 | 258.88 | 988.40K |
| Oct 7, 2026 | 261.41 | 261.41 | 255.05 | 258.11 | 1.41M |
| Oct 6, 2026 | 269.43 | 274.28 | 259.79 | 259.98 | 1.11M |
| Oct 5, 2026 | 258.51 | 266.91 | 258.51 | 266.09 | 1.69M |
| Oct 2, 2026 | 260.70 | 261.98 | 257.07 | 258.21 | 1.37M |
| Oct 1, 2026 | 268.02 | 268.88 | 259.31 | 260.72 | 1.48M |
| Sep 30, 2026 | 269.96 | 273.16 | 267.61 | 268.85 | 1.53M |
| Sep 29, 2026 | 271.46 | 273.50 | 266.43 | 268.99 | 1.17M |
| Sep 28, 2026 | 266.52 | 272.75 | 265.97 | 270.97 | 1.62M |
| Sep 25, 2026 | 274.90 | 274.90 | 269.43 | 270.37 | 1.10M |
| Sep 24, 2026 | 266.46 | 277.13 | 266.46 | 275.02 | 1.89M |
| Sep 23, 2026 | 270.66 | 277.40 | 267.42 | 267.86 | 1.12M |
| Sep 22, 2026 | 270.25 | 272.44 | 267.26 | 270.09 | 950.70K |
| Sep 21, 2026 | 266.76 | 270.86 | 265.25 | 269.88 | 1.93M |
About Iqvia
Iqvia (IQV) is listed on the NYSE and classified by the SEC under “Services-Commercial Physical & Biological Research”. Its business address is in DURHAM, NC. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1478242.
IQV board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ari Bousbib | See Remarks | Jul 31, 2026 |
| Carol Burt | Director | Apr 27, 2026 |
| John G Danhakl | Director | Jul 16, 2026 |
| Jim Fasano | Director | Jul 16, 2026 |
| Colleen A Goggins | Director | Jul 16, 2026 |
| William G Jr Kaelin | Director | Apr 27, 2026 |
| John M Leonard | Director | Apr 27, 2026 |
| Sheila A Stamps | Director | Apr 27, 2026 |
| Morris Leslie Wims | Director | Jul 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ari Bousbib | See Remarks | Jul 31, 2026 |
| James G. Berkshire | See Remarks | Sep 4, 2026 |
| Ronald E Bruehlman | See Remarks | Feb 10, 2026 |
| Keriann Cherofsky | See Remarks | Jul 31, 2026 |
| Michael J. Fedock | See Remarks | Feb 17, 2026 |
| Alistair Grenfell | See Remarks | Feb 11, 2026 |
| Bernd Haas | See Remarks | Feb 17, 2026 |
| Bhavik Patel | See Remarks | Aug 4, 2026 |
| W Richard Staub | See Remarks | Aug 4, 2026 |
| Eric Sherbet | See Remarks | Jul 31, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | James G. Berkshire | Sale | 2,668 | $261.33 |
| Sep 2, 2026 | James G. Berkshire | Sale | 2,668 | $261.33 |
| Sep 2, 2026 | James G. Berkshire | Sale | 2,668 | $261.33 |
| Sep 2, 2026 | James G. Berkshire | Sale | 2,668 | $261.33 |
| Aug 3, 2026 | W Richard Staub | Sale | 5,500 | $232.68 |
| Aug 3, 2026 | W Richard Staub | Sale | 5,500 | $232.68 |
| Aug 3, 2026 | W Richard Staub | Sale | 5,500 | $232.68 |
| Aug 3, 2026 | W Richard Staub | Sale | 5,500 | $232.68 |
| Jul 31, 2026 | Bhavik Patel | Sale | 1,855 | $235.27 |
| Jul 31, 2026 | Bhavik Patel | Sale | 1,855 | $235.27 |
| Jul 31, 2026 | Bhavik Patel | Sale | 1,855 | $235.27 |
| Jul 31, 2026 | Bhavik Patel | Sale | 1,855 | $235.27 |
| Jul 29, 2026 | Ari Bousbib | Sale | 44,039 | $246.08 |
| Jul 29, 2026 | Ari Bousbib | Sale | 53,191 | $244.78 |
| Jul 29, 2026 | Ari Bousbib | Sale | 4,465 | $247.10 |
IQV financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $16.31B | $1.36B | 7.84 | $2.65B |
| Dec 31, 2024 | $15.40B | $1.37B | 7.49 | $2.72B |
| Dec 31, 2023 | $14.98B | $1.36B | 7.29 | $2.15B |
| Dec 31, 2022 | $14.41B | $1.09B | 5.72 | $2.26B |
| Dec 31, 2021 | $13.87B | $966.00M | 4.95 | $2.94B |
Latest balance sheet: total assets $29.68B, total liabilities $23.33B, cash $1.95B (as of Mar 31, 2026).
IQV earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 28, 2026 | 8-K Item 2.02 (results) | $242.94 |
| May 5, 2026 | 8-K Item 2.02 (results) | $176.42 |
| Feb 5, 2026 | 8-K Item 2.02 (results) | $180.96 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $218.13 |
| Jul 22, 2025 | 8-K Item 2.02 (results) | $187.38 |
| May 6, 2025 | 8-K Item 2.02 (results) | $146.20 |
| Feb 6, 2025 | 8-K Item 2.02 (results) | $209.96 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $205.82 |
| Jul 22, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Commercial Physical & Biological Research
Charles River Laboratories International (CRL)Incyte (INCY)Icon (ICLR)Medpace (MEDP)Absci (ABSI)bioAffinity Technologies (BIAF)OmniAb (OABI)Nrc Health (NRC)Maxcyte (MXCT)iSpecimen (ISPC)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IQV
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.